...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith Email this morning

"The only thing keeping me invested is my belief at some point a BP will take a stab at a major partnership with either Zenith, RVX or both,.."

Yes if they can sustain the financial hardship they both face at present and as it seems, will for some time to come. 

 

Koo

Share
New Message
Please login to post a reply